ClinicalTrials.gg
RecruitingNCT06155084Updated Dec 22, 2025

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

A Phase 1/2 interventional study of HP518 - Dose Escalation and HP518 - Dose Escalation in Metastatic Castration-resistant Prostate Cancer, sponsored by Hinova Pharmaceuticals Inc.. Recruiting at 27 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Hinova Pharmaceuticals Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 542 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 52 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
240th of 436
84 · median 100
Started
2023
with 58 others
Phase 1/2
52 of 542
30 open now
Primary completion
2026-03
later than 99 of 341 live
Registered
266th of 542
by date

Among the 542 studies in Prostatic Neoplasms with a site in China, this one is the 240th largest by planned enrollment of the 436 interventional ones that give a count, is one of 59 that started in 2023, is one of 52 in phase 1/2, reaches primary completion later than 99 of the 341 other live ones, and was the 266th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 542 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

276 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 542 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

The overall objective of this Phase 1 study is to evaluate the safety, PK,and anti-tumor activity of daily oral dosing with HP518,selecting the RP2D of HP518 based on assessments of patients with progressive mCRPC in dose-escalation phase

Read the detailed description

This First in Human dose escalation and expansion study of HP518 in patients with progressive mCRPC after NHA and chemotherapy is being conducted not only to evaluate the safety and tolerability of orally administered HP518, but also to provide preliminary efficacy for the reference of future studies.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, age ≥18
  2. Patients with androgen receptor (AR) ligand binding domain (LBD) activation mutations (the dose expansion part of stage II)
  3. Has confirmed adenocarcinoma of the prostate, but there are no known significant neuroendocrine differentiation or small cell characteristics.
  4. Has disease documented by 2 or more bone lesions by bone scan or soft tissue disease progression observed by CT/MRI at the beginning of study.
  5. the progression of the disease after receiving at least one new endocrine therapy and progressing with at least chemotherapy.
  6. Must have recovered from toxicities related to any prior treatments
  7. Ongoing ADT with LHRH agonist/antagonist therapy or history of bilateral orchiectomy.
  8. performance status score of 0 to 1.

Exclusion criteria

Exclusion Criteria:

  1. Combination of research or commercially available drugs targeting AR
  2. Has had any other anticancer treatments, including immunotherapy, chemotherapy, or radiotherapy (eg, 177LuPSMA-617, radium 223, PARP inhibitor) within 4 weeks prior to the first dose of HP518.
  3. Has gastrointestinal disorder affecting absorption (e.g., gastrectomy).
  4. Has significant cardiovascular disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Part 1 - Dose Escalation, 400mg/d (Cohort1)

    Oral tablet(s), once daily in 28-day cycles

    Drug: HP518 - Dose Escalation

  • Experimental
    Part 1 - Dose Escalation 500mg/d (Cohort 2)

    Oral tablet(s), once daily in 28-day cycles

    Drug: HP518 - Dose Escalation

  • Experimental
    Part 2 - Dose Expansion Oral tablet(s)

    Oral tablet(s), once daily in 28-day cycles

    Drug: HP518 -Dose Expansion

Interventions

  • DrugHP518 - Dose Escalation

    Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort

    Also known as: Part 1 - Dose Escalation

  • DrugHP518 - Dose Escalation

    Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort

    Also known as: Part 1 - Dose Escalation

  • DrugHP518 -Dose Expansion

    Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.

    Also known as: Part 2 - Dose Expansion Oral tablet(s)

06

What researchers measure

Primary outcomes

  1. Incidences of Protocol-defined DLT during the DLT assessment period , characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drugorally administered HP518 (Part 1)

    To evaluate the safety and tolerability and determine the MTD and the RP2D of orally administered HP518 (Part 1)

    Time frame: 28 DAYS

  2. Incidence of Treatment-Emergent Adverse Events characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness

    To evaluate the safety of orally administered HP518 (Part 1)

    Time frame: Through study completion, an average of 1 year

  3. Incidence of laboratory abnormalities, characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing

    To evaluate the safety of orally administered HP518 (Part 1)

    Time frame: Through study completion, an average of 1 year

  4. Incidence of vital signs abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing

    To evaluate the safety of orally administered HP518 (Part 1)

    Time frame: Through study completion, an average of 1 year

  5. Incidence of ECG (PR, QRS, QT, and QTcF intervals) abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing

    To evaluate the safety of orally administered HP518 (Part 1)

    Time frame: Through study completion, an average of 1 year

  6. PSA50 response rate

    Proportion of patients showing a PSA decline by ≥50% between baseline and Week 12 of dosing with HP518.

    Time frame: 12 weeks

Secondary outcomes

  1. area under the concentration-time curve (AUC)

    Assessment of pharmacokinetic parameters of HP518

    Time frame: 12 weeks

  2. Maximum concentration (Cmax)

    Assessment of pharmacokinetic parameters of HP518

    Time frame: 12 weeks

  3. Time to maximum concentration (Tmax)

    Assessment of pharmacokinetic parameters of HP518

    Time frame: 12 weeks

  4. Apparent terminal elimination half-life (T1/2)

    Assessment of pharmacokinetic parameters of HP518

    Time frame: 12 weeks

  5. apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

    Assessment of pharmacokinetic parameters of HP518

    Time frame: 12 weeks

  6. oral clearance (CL/F)

    Assessment of pharmacokinetic parameters of HP518

    Time frame: 12 weeks

  7. According to PCWG3

    evaluate PSA50 response rate: PSA decline by≥50% between baseline and 4 weeks/8 weeks/12 weeks( only Part 1) of dosing with HP518

    Time frame: 8 weeks

  8. According to PCWG3, evaluate time to PSA progression

    PCWG3 definition: PSA increase \>25% and \>2 ng/mL above nadir, confirmed by progression at 2 time points at least 3 weeks apart) nadir, confirmed by progression at 2 time points at least 3 weeks apart)

    Time frame: Through study completion, an average of 1 year

  9. Time to radiographic progression by investigator PCWG3 definition

    using the RECIST v1.1 and PCWG3 definition

    Time frame: Through study completion, an average of 1 year

  10. Evaluate the modified best overall response mBOR by investigator

    According to RECIST (version 1.1) and PCWG3

    Time frame: Through study completion, an average of 1 year

  11. analyze the efficacy of patients with different AR phenotypes(Part 2)

    According to genetic testing results

    Time frame: Through study completion, an average of 1 year

07

Study locations

26 of 27 sites recruiting
  • The Second Hospital Of Anhui Medical University
    Hefei, Anhui, China
    Recruiting
    • Dexin Yu · Principal investigator
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • Jun Guo · Principal investigator
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
    Recruiting
    • Yinong Niu · Principal investigator
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing Municipality, China
    Recruiting
    • Hong Luo · Principal investigator
  • The Second Affiliated Hospital Of Chongqing Medical University
    Chongqing, Chongqing Municipality, China
    Recruiting
    • Xian Yu · Principal investigator
    • Qing Jiang · Principal investigator
  • The First Affiliated Hospital Of Xiamen Univeristy
    Xiamen, Fujian, China
    Not yet recruiting
    • Jinchun Xing · Principal investigator
  • Lanzhou University Second Hospital
    Lanzhou, Gansu, China
    Recruiting
    • Li Yang · Principal investigator
  • The Third Affiliated Hospital of Southern Medical University
    Guangzhou, Guangdong, China
    Recruiting
    • Cundong Liu · Principal investigator
  • The Affiliated Hospital Of Guizhou Medical University
    Guiyang, Guizhou, China
    Recruiting
    • Qiang Wang · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Tiejun Yang · Principal investigator
  • Zhengzhou Central Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Kai Zhang · Principal investigator
  • Tongji Hospital
    Wuhan, Hubei, China
    Recruiting
    • Zhiquan Hu · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan, China
    Recruiting
    • Shusuan Jiang · Principal investigator
  • The First Affiliated Hospital Of Nanchang University
    Nanchang, Jiangxi, China
    Recruiting
    • Cheng Zhang · Principal investigator
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning, China
    Recruiting
    • Yu Zeng · Principal investigator
  • Shandong Provincial Hospital
    Jinan, Shandong, China
    Recruiting
    • Hao Ning · Principal investigator
  • The Affiliated Hospital Of Qingdao University
    Qingdao, Shandong, China
    Recruiting
    • Haitao Niu · Principal investigator
  • Yantai Yuhuangding Hospital
    Yantai, Shandong, China
    Recruiting
    • Jitao Wu · Principal investigator
  • Shanghai Tenth People's Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Xudong Yao · Principal investigator
  • The First Affiliated Hospital Of Xi'An Jiaotong Univeristy
    Xi’an, Shanxi, China
    Recruiting
    • Lei Li · Principal investigator
  • Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
    Recruiting
    • Jing Liu · Principal investigator
  • West China Hospital Of Sichuan University
    Chengdu, Sichuan, China
    Recruiting
    • Qiang Dong · Principal investigator
    • Ping Feng · Principal investigator
  • The Affiliated Hospital Of Southwest Medical University
    Luzhou, Sichuan, China
    Recruiting
    • Peng Qing · Principal investigator
  • Mianyang Central Hospital
    Mianyang, Sichuan, China
    Recruiting
    • Xiaobo Du · Principal investigator
  • The Second Affiliated Hospital Of Kunming Medical University
    Kunming, Yunnan, China
    Recruiting
    • Changxing Ke · Principal investigator
  • The Affiliated Hospital Of School Of Medicine Of Ningbo University
    Ningbo, Zhejiang, China
    Recruiting
    • Zejun Yan · Principal investigator
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
    Recruiting
    • Wei Chen · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Mar 2026, 27 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 27 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2023
First posted
Dec 4, 2023
StartActual
Dec 26, 2023
Primary completionEst.
Mar 2026
CompletionEst.
Sep 2026
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06155084
Lead sponsor
Hinova Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Dec 4, 2023
Start date
Dec 26, 2023
Primary completion
Mar 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Dec 22, 2025

Study contacts

Qianrong Xiang
Contact
qrxiang@hinovapharma.com
+86 28 8505 8465

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion